Veronika Mantziou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Veronika Mantziou has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso Martinez Arias
Department of Medicine and Life Sciences, Universitat Pompeu Fabra and ICREA, Barcelona, Spain
3 shared publications - Manuela Jaklin
Pharmaceutical Sciences, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland
2 shared publications - Naomi Moris
The Francis Crick Institute, London, UK
2 shared publications - Peter Baillie-Johnson
Department of Genetics, University of Cambridge, Cambridge, UK
2 shared publications Naomi Moris
Department of Genetics, University of Cambridge, Cambridge, CB2 3EH, UK
1 shared publication- Sabitri Ghimire
Université de Strasbourg, IGBMC UMR 7104- UMR-S 1258 1 , Developmental Biology and Stem Cells Department, F-67400 Illkirch
1 shared publication
Latest Publications
- Open Access
- 1 October 2021
- Published by Elsevier in Reproductive Toxicology
- Vol. 105, 72-90
In vitro teratogenicity testing using a 3D, embryo-like gastruloid system
- 1 October 2021
- Published by Elsevier in Reproductive Toxicology
- Vol. 105, 72-90
Open AccessIn vitro teratogenicity testing using a 3D, embryo-like gastruloid system
- 1 June 2021
- Published by Elsevier in Developmental Biology
- Vol. 474, 100-108
Human gastrulation: The embryo and its models
- 1 June 2021
- Published by Elsevier in Developmental Biology
- Vol. 474, 100-108
Human gastrulation: The embryo and its models
- Open Access
In vitro teratogenicity testing using a 3D, embryo-like gastruloid system
Pharmaceuticals that are intended for use in patients of childbearing potential need to be tested for teratogenicity before marketing. Several pharmaceutical companies use animal-free in vitro models which allow a more rapid selection of lead compounds and contribute to 3Rs principles (‘replace, reduce and refine’) by streamlining the selection of promising compounds that are submitted to further regulatory studies in animals. Currently available in vitro models typically rely on adherent monolayer cultures or disorganized 3D structures, both of which lack the spatiotemporal and morphological context of the developing embryo. A newly developed 3D ‘gastruloid’ model has the potential to achieve a more reliable prediction of teratogenicity by providing a robust recapitulation of gastrulation-like events alongside morphological coordination at relatively high-throughput. In this first proof-of-concept study, we used both mouse and human gastruloids to examine a panel of seven reference compounds, with associated in vivo data and known teratogenic risk, to quantitatively assess in vitro teratogenicity. We observed several gross morphological effects, including significantly reduced elongation or decreased size of the gastruloids, upon exposure to several of the reference compounds. We also observed aberrant gene expression using fluorescent reporters, including SOX2, BRA , and SOX17 , suggestive of multi-lineage differentiation defects and disrupted axial patterning. Finally, we saw that gastruloids recapitulated some of the known in vivo species-specific susceptibilities between their mouse and human counterparts. We therefore suggest that gastruloids represent a powerful tool for teratogenicity assessment by enabling relevant physiological recapitulation of early embryonic development, demonstrating their use as a novel in vitro teratogenic model system.
Open AccessIn vitro teratogenicity testing using a 3D, embryo-like gastruloid system
Pharmaceuticals that are intended for use in patients of childbearing potential need to be tested for teratogenicity before marketing. Several pharmaceutical companies use animal-free in vitro models which allow a more rapid selection of lead compounds and contribute to 3Rs principles (‘replace, reduce and refine’) by streamlining the selection of promising compounds that are submitted to further regulatory studies in animals. Currently available in vitro models typically rely on adherent monolayer cultures or disorganized 3D structures, both of which lack the spatiotemporal and morphological context of the developing embryo. A newly developed 3D ‘gastruloid’ model has the potential to achieve a more reliable prediction of teratogenicity by providing a robust recapitulation of gastrulation-like events alongside morphological coordination at relatively high-throughput. In this first proof-of-concept study, we used both mouse and human gastruloids to examine a panel of seven reference compounds, with associated in vivo data and known teratogenic risk, to quantitatively assess in vitro teratogenicity. We observed several gross morphological effects, including significantly reduced elongation or decreased size of the gastruloids, upon exposure to several of the reference compounds. We also observed aberrant gene expression using fluorescent reporters, including SOX2, BRA , and SOX17 , suggestive of multi-lineage differentiation defects and disrupted axial patterning. Finally, we saw that gastruloids recapitulated some of the known in vivo species-specific susceptibilities between their mouse and human counterparts. We therefore suggest that gastruloids represent a powerful tool for teratogenicity assessment by enabling relevant physiological recapitulation of early embryonic development, demonstrating their use as a novel in vitro teratogenic model system.